SEATTLE, WASHINGTON - A new metastatic melanoma study suggests that a combination of two immunotherapies may be better than one:
Researchers at Fred Hutchinson Cancer Research Center in Seattle say the study, conducted between 2011 and 2013, "opens the door" to more studies of combination immunotherapy to fight metastatic melanoma and possibly other cancers.
The findings will appear in the Journal of Clinical Oncology and are embargoed until Monday, June 6 at 4 p.m. ET.
KEY FINDINGS:
Of 10 study participants:
"This suggests that you can probably 'rescue' patients who do not respond to one form of treatment by doing combinations," says Dr. Aude Chapuis, first author, a medical oncologist and an adult hematopoietic stem cell transplant (HCT) physician with a strong background in immunology and adoptive T-cell transfer studies in humans.
###
Journal of Clinical Oncology